Charles River Laboratories

   
 
 
   
   

Charles River Announces Second-Quarter 2008 Results

Downloadable version.

  • Second-Quarter Sales Increase 14.5% to $352 Million
  • Second-Quarter GAAP EPS Increase 29% to $0.71 and Non-GAAP EPS Increase 23% to $0.79
  • Raising 2008 Sales and Non-GAAP EPS Guidance, GAAP EPS Guidance Lowered
  • Agreement Signed to Acquire NewLab BioQuality AG
  • Increases Stock Repurchase Authorization by $200 Million

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 5, 2008--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter and first six months of 2008. For the quarter, net sales increased 14.5% to $352.1 million from $307.4 million in the second quarter of 2007. Both the Research Models and Services (RMS) and Preclinical Services (PCS) business segments reported significantly higher sales, with the RMS segment showing particular strength due to continued demand from pharmaceutical and biotechnology companies. Foreign exchange contributed 4.1% to the net sales growth.

Click here to read the full release.
   
Discover the full range of Charles River Products and Services

For more information please call:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Mar 01 - New Technical Resources Section Av...
Jan 11 - Charles River to Suspend Operation...
Mar 22-Mar 23 - San Francisco, CA - 2010 PMF Bacterial Endotoxin Summit
Mar 15-Mar 19 - Orlando, FL - 2010 PDA Annual Meeting
May 05-May 05 - Tempe, AZ - Rodent Colony and Disease Management Considerations – A Sem...
view all
Corporate Sr. VP, Corporate Development 
Corporate VP, Corporate Tax Wilmington, M...

Charles River Laboratories, Inc.